ArticleBMC cancer2025
Magnetic sentinel lymph node detection using superparamagnetic iron oxide in early-stage oral squamous cell carcinoma: design and rationale of the multicenter magnetics trial - study protocol.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundSentinel lymph node (SLN) biopsy is a diagnostic staging procedure in early-stage oral squamous cell carcinoma (OSCC). The conventional method using tracers labeled with 99mTc is limited by the’shine-through’ phenomenon, a situation where intense tracer uptake at the injection site obscures nearby lymph nodes, making them difficult to detect. This effect is particularly problematic in floor of mouth tumors, where the sentinel nodes are often located close to the primary tumor. Tracing lymphatic drainage of the tumor with superparamagnetic iron oxide nanoparticles (SPIO) in combination with magnetic resonance imaging (MRI) provides superior anatomical detail over the use of radioactive tracers, which may improve the detection of SLNs. This multicenter clinical trial aims to evaluate the diagnostic accuracy of a complete magnetic SLN biopsy procedure in early-stage OSCC.
methodsThis prospective multicenter trial will enroll 82 patients with early-stage OSCC undergoing transoral resection and SLN biopsy. The complete magnetic SLN biopsy procedure includes peritumoral SPIO injection, preoperative SPIO-enhanced magnetic resonance (MR) lymphography, and intraoperative SLN detection by a magnetometer. Results will be compared to the conventional SLN biopsy using a [99mTc]Tc-nanocolloid tracer and indocyanine green. Sensitivity, negative predictive value (NPV), interobserver reliability, and patient perspectives will be assessed. DISCUSSION: A complete magnetic SLN biopsy may improve staging accuracy in OSCC by addressing radiotracer limitations and potentially reducing false-negative rates. This technique could potentially be expanded to other cancers, offering a radiation-free alternative to conventional SLN biopsy methods.
trial registrationThis trial is approved by the Medical Research Ethical Committee NedMec (number: 2023/157) and registered in the Netherlands Trial Register (registration number: NL81165.041.22).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.